{
    "name": "rituximab",
    "comment": "Rx",
    "other_names": [
        "Rituxan",
        "Truxima",
        "rituximab-abbs",
        "Ruxience",
        "rituximab-pvvr",
        "rituximab-arrx",
        "Riabni"
    ],
    "classes": [
        "DMARDs",
        "Other",
        "Antineoplastics",
        "Anti-CD20 Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/rituxan-truxima-rituximab-342243",
    "pregnancy": {
        "common": [
            "Verify pregnancy status in females of reproductive potential prior to initiating therapy",
            "Based on human data, can cause adverse developmental outcomes including B-cell lymphocytopenia in infants exposed to rituximab in-utero",
            "Observe newborns and infants for signs of infection and manage accordingly"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "IV administration to pregnant cynomolgus monkeys during organogenesis caused lymphoid B-cell depletion in newborn offspring at doses resulting in 80% of exposure (based on AUC) of those achieved following a 2 gram-dose in humans",
                    "Advise pregnant females of the risk to a fetus"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of childbearing potential: Use effective contraception during and for 12 months following treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data unavailable on drug presence in human milk, effects on breastfed children, or effects on milk production",
            "Detected in the milk of lactating cynomolgus monkeys, and IgG is present in human milk",
            "Rituximab reported to be excreted at low concentrations in human breast milk; given that clinical significance of this finding for children is not known, advise women not to breastfeed during treatment and for 6 months after last dose due to potential of serious adverse reactions in breastfed children"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Fatal infusion reaction",
                    "description": [
                        "Can result in serious, including fatal reactions",
                        "Deaths within 24 hr of infusion have occurred",
                        "Approximately 80% of fatal infusion reactions occurred in association with the first infusion",
                        "Carefully monitor patients during infusion",
                        "In patients with NHL receiving rituximab monotherapy, grade 3 and 4 cytopenias reported; reactions included lymphopenia, neutropenia, leukopenia, anemia, and thrombocytopenia; discontinue infusion and provide medical treatment for grade 3 or 4 reactions"
                    ]
                },
                {
                    "type": "Severe mucocutaneous reactions",
                    "description": [
                        "Severe, including fatal, mucocutaneous reactions reported including paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis"
                    ]
                },
                {
                    "type": "Progressive multifocal leukoencephalopathy",
                    "description": [
                        "John Cunningham virus infection resulting in progressive multifocal leukoencephalopathy and death has been reported in patients treated with rituximab"
                    ]
                },
                {
                    "type": "Hepatitis B virus reactivation",
                    "description": [
                        "Reactivation of hepatitis B virus (HBV) infection reported, including deaths",
                        "Screen all patients for HBV infection before initiating drug by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc)",
                        "Consult with hepatitis experts regarding monitoring and use of HBV antiviral therapy when screening identifies patients at risk of HBV reactivation due to evidence of prior HBV infection",
                        "Monitor patients with evidence of prior HBV infection for clinical and laboratory signs of hepatitis B or HBV reactivation during therapy and for several months thereafter, since reactivations have occurred several months following completion of therapy",
                        "In patients who develop reactivation of HBV, immediately discontinue drug and start appropriate HBV treatment, also discontinue any chemotherapy until the HBV infection is controlled or resolved",
                        "Because of insufficient data, no recommendation can be made regarding the resumption of the drug in patients who develop HBV reactivation"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Severe, including fatal, infusion-related reactions may occur; severe reactions typically occurred during the first infusion with time to onset of 30-120 minutes; premedicate as recommended according to indication; have appropriate medical management available if reaction occurs (eg, glucocorticoids, epinephrine, bronchodilators, oxygen) (see Black Box Warnings and Administration); methylprednisolone 100 mg intravenously or its equivalent recommended 30 min prior to each infusion",
                "Risk of potentially fatal mucocutaneous reactions (see Black Box Warnings)",
                "Increased risk of potentially fatal hepatitis B virus reactivation (see Black Box Warnings)",
                "Potential risk of progressive multifocal leukoencephalopathy (see Black Box Warnings)",
                "Risk of potentially fatal tumor lysis syndrome",
                "Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of therapy; not recommended for patients with severe, active infections",
                "Cardiac adverse reactions (eg, ventricular fibrillation, myocardial infarction, cardiogenic shock) may occur; discontinue infusions for serious or life-threatening cardiac arrhythmias; cardiac monitoring needed during and after all infusions patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina",
                "Severe, including fatal, renal toxicity can occur after administration in patients with NHL; renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials; the combination of cisplatin and rituximab is not an approved treatment regimen",
                "Abdominal pain, bowel obstruction and perforation reported, including cases leading to death",
                "Based on human data, rituximab can cause fetal harm owing to B-cell lymphocytopenia in infants exposed in utero (see Pregnancy)",
                "A favorable risk-benefit relationship has not been established in in patients with RA with prior inadequate responses to nonbiologic DMARDs; use in these patients is not recommended",
                "Hypogammaglobulinemia has been observed in pediatric patients treated with rituximab",
                "Majority of patients with hematologic malignancies diagnosed with PML received rituximab in combination with chemotherapy or as part of a hematopoietic stem cell transplant; patients with autoimmune diseases had prior or concurrent immunosuppressive therapy; most cases of PML were diagnosed within 12 months of their last infusion of rituximab"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Safety of immunization with live viral vaccines following rituximab has not been studied and vaccination with live virus vaccines is not recommended before or during treatment; for patients with RA, follow current immunization guidelines and administer non-live vaccines at least 4 weeks before treatment",
                        "Limited data are available on the safety of the use of biologic agents or disease modifying antirheumatic drugs (DMARDs) other than methotrexate in RA patients exhibiting peripheral B-cell depletion following treatment; observe closely for signs of infection if biologic agents and/or DMARDs are used concomitantly"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "rituximab, adenovirus types 4 and 7 live, oral. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "rituximab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baricitinib",
            "description": {
                "common": "baricitinib, rituximab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "rituximab, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "rituximab and certolizumab pegol both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "rituximab, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "rituximab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "rituximab, influenza virus vaccine quadrivalent, intranasal. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "rituximab, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "rituximab, measles (rubeola) vaccine. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "rituximab, measles mumps and rubella vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "rituximab, measles, mumps, rubella and varicella vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of rituximab by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, rituximab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "rituximab, rotavirus oral vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "rituximab, rubella vaccine. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "rituximab, smallpox (vaccinia) vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "rituximab, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and rituximab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Each drug is an anti-CD20 monoclonal antibody indicated for multiple sclerosis. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "rituximab, varicella virus vaccine live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "rituximab, yellow fever vaccine. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "rituximab, zoster vaccine live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "amphotericin B deoxycholate and rituximab both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Caution should be exercised when concurrent therapy is used. Patients should be monitored for signs of renal failure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept and rituximab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "rituximab, cholera vaccine. immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "cisplatin and rituximab both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Potential for renal toxicity when used in combination with cisplatin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "rituximab decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "denosumab",
            "description": {
                "common": "rituximab, denosumab. Other (see comment). Use Caution/Monitor. \nComment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of rituximab by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "rituximab increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis A vaccine inactivated",
            "description": {
                "common": "rituximab, hepatitis A vaccine inactivated. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis a/b vaccine",
            "description": {
                "common": "rituximab, hepatitis a/b vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis b vaccine",
            "description": {
                "common": "rituximab, hepatitis b vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "HIV vaccine",
            "description": {
                "common": "rituximab, HIV vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "human papillomavirus vaccine, nonavalent",
            "description": {
                "common": "rituximab, human papillomavirus vaccine, nonavalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "human papillomavirus vaccine, quadrivalent",
            "description": {
                "common": "rituximab, human papillomavirus vaccine, quadrivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza A (H5N1) vaccine",
            "description": {
                "common": "rituximab, influenza A (H5N1) vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine (H5N1), adjuvanted",
            "description": {
                "common": "rituximab, influenza virus vaccine (H5N1), adjuvanted. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent",
            "description": {
                "common": "rituximab, influenza virus vaccine quadrivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "rituximab, influenza virus vaccine quadrivalent, adjuvanted. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, cell-cultured",
            "description": {
                "common": "rituximab, influenza virus vaccine quadrivalent, cell-cultured. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent",
            "description": {
                "common": "rituximab, influenza virus vaccine trivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "rituximab, influenza virus vaccine trivalent, adjuvanted. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ioversol",
            "description": {
                "common": "ioversol and rituximab both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "Japanese encephalitis virus vaccine",
            "description": {
                "common": "rituximab, Japanese encephalitis virus vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine, rituximab.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration with mechlorethamine may increase the risk of immunosuppression and myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, rituximab.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "poliovirus vaccine inactivated",
            "description": {
                "common": "rituximab decreases effects of poliovirus vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response may be suboptimal. Patients on chemotherapy with anti-B cell antibodies should wait =6 months after therapy before being vaccinated with inactivated vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and rituximab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies vaccine",
            "description": {
                "common": "rituximab, rabies vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies vaccine chick embryo cell derived",
            "description": {
                "common": "rituximab, rabies vaccine chick embryo cell derived. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and rituximab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "rituximab decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, rituximab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, rituximab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine recombinant",
            "description": {
                "common": "rituximab, zoster vaccine recombinant. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Angioedema",
            "percent": "11"
        },
        {
            "name": "Asthenia",
            "percent": "26"
        },
        {
            "name": "chills",
            "percent": "33"
        },
        {
            "name": "dizziness",
            "percent": "10"
        },
        {
            "name": "fever",
            "percent": "53"
        },
        {
            "name": "headache",
            "percent": "19"
        },
        {
            "name": "Pruritus",
            "percent": "14"
        },
        {
            "name": "rash",
            "percent": "15"
        },
        {
            "name": "Abdominal pain",
            "percent": "14"
        },
        {
            "name": "diarrhea",
            "percent": "10"
        },
        {
            "name": "nausea",
            "percent": "23"
        },
        {
            "name": "vomiting",
            "percent": "10"
        },
        {
            "name": "Leukopenia",
            "percent": "14"
        },
        {
            "name": "lymphopenia",
            "percent": "48"
        },
        {
            "name": "neutropenia",
            "percent": "14"
        },
        {
            "name": "thrombocytopenia",
            "percent": "12"
        },
        {
            "name": "Back pain",
            "percent": "10"
        },
        {
            "name": "myalgia",
            "percent": "10"
        },
        {
            "name": "Cough",
            "percent": "13"
        },
        {
            "name": "rhinitis",
            "percent": "12"
        },
        {
            "name": "Infection",
            "percent": "31"
        },
        {
            "name": "night sweats",
            "percent": "15"
        },
        {
            "name": "Nausea",
            "percent": "18"
        },
        {
            "name": "Diarrhea",
            "percent": "17"
        },
        {
            "name": "Headache",
            "percent": "17"
        },
        {
            "name": "Muscle spasms",
            "percent": "17"
        },
        {
            "name": "Anemia",
            "percent": "16"
        },
        {
            "name": "Peripheral edema",
            "percent": "16"
        },
        {
            "name": "Insomnia",
            "percent": "14"
        },
        {
            "name": "Arthralgia",
            "percent": "13"
        },
        {
            "name": "Cough",
            "percent": "13"
        },
        {
            "name": "Fatigue",
            "percent": "13"
        },
        {
            "name": "Increased ALT",
            "percent": "13"
        },
        {
            "name": "Hypertension",
            "percent": "12"
        },
        {
            "name": "Epistaxis",
            "percent": "11"
        },
        {
            "name": "Infusion reactions",
            "percent": "58"
        },
        {
            "name": "Depression",
            "percent": "18"
        },
        {
            "name": "Herpes simplex",
            "percent": "13"
        },
        {
            "name": "Alopecia",
            "percent": "13"
        },
        {
            "name": "Edema",
            "percent": "10"
        },
        {
            "name": "Flushing",
            "percent": "10"
        },
        {
            "name": "Hypertension",
            "percent": "10"
        },
        {
            "name": "Anxiety",
            "percent": "8"
        },
        {
            "name": "Anemia",
            "percent": "5"
        },
        {
            "name": "Elevated LDH",
            "percent": "5"
        },
        {
            "name": "Hyperglycemia",
            "percent": "5"
        },
        {
            "name": "Bronchospasm",
            "percent": "5"
        },
        {
            "name": "dyspnea",
            "percent": "5"
        },
        {
            "name": "sinusitis",
            "percent": "5"
        },
        {
            "name": "throat irritation",
            "percent": "5"
        },
        {
            "name": "urticaria",
            "percent": "5"
        },
        {
            "name": "Hypertension",
            "percent": "5"
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "asthenia",
            "percent": null
        },
        {
            "name": "chills",
            "percent": null
        },
        {
            "name": "migraine",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "pyrexia",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "upper abd pain",
            "percent": null
        },
        {
            "name": "Hypercholesterolemia",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Rhinitis",
            "percent": null
        },
        {
            "name": "throat irritation",
            "percent": null
        },
        {
            "name": "URI",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Upper abdominal pain",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "headache",
            "percent": null
        },
        {
            "name": "Herpes zoster",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        },
        {
            "name": "Muscular pain",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "skin disorder",
            "percent": null
        },
        {
            "name": "skin papilloma",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        }
    ]
}